Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound’s cash sales
If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
- Who's exposed
- LLYEli Lilly and Down
Companies named in the story.
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
